GPE
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
Investments, China, Evaluation procedure
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases
AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts
Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Otsuka’s Taiho pays $400M for Swiss partner to ‘turbocharge’ 3 ADCs to clinic
Araris, Taiho, Antibody-Drug Conjugates, Otsuka ‘s, Acquisition (action), ADCs, ADC
Insilico secures $110M in new funding for AI-designed pipeline
Clinical Trials, Aortic Valve Insufficiency
Merck opens $1B Gardasil manufacturing facility in North Carolina
Merck, Facility (object), Manufacture, Durham, North Carolina
UPDATE: DOGE quietly decreases savings estimate for 30 terminated FDA leases
Financial savings, United States Food and Drug Administration, DOGE, Estimated, leases, terminated – RoleStatus, St. Louis, DOGE ‘s
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup
Challenges in Moving Pharmaceutical Manufacturing to the US
Bavarian Nordic, pharmaceutical manufacturing, US relocation, time constraints, infrastructure limitations